The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma.

摘要: Abstract Background and purpose : To compare the biochemical outcomes of patients treated with Pd-103/I-125 brachytherapy alone vs. combined external beam radiotherapy for early stage prostate carcinoma. Methods Brachytherapy monotherapy was used in 403 patients. 45 Gy 231 Median follow-up 58 months. these two treatment approaches, were stratified into three relative risk groups: low risk, T 1 –T 2 , Gleason 2–6/10, PSA≤10.0; intermediate 3 7–10/10, PSA>10.0 (one factor); high (two factors). Results The actuarial progression-free rate (bNED) entire 634 85% at 10 years. bNED by group therapy respectively were: 94 87%; 84 85%; 54 62%. These differences did not reach statistical significance any group. Rectal morbidity slightly greater Conclusion Although addition irradiation to is conceptually appealing higher carcinoma, we unable demonstrate a benefit. Whether this because patient selection biases within groupings, an artefact retrospective review, or does offer additional benefit uncertain.